Synapse - Gregory Riely

Search Within

Gregory J Riely

Results (599)

Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC)

Meeting Abstract

Solomon, B. J.; Gettinger, S. N.; Riely, G. J.; Gadgeel, S. M.; Nokihara, H.; Han, J. Y.; Hida, T.; Satouchi, M.; Baldini, E.; Siena, S.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Response to erlotinib and prognosis for patients with de novo epidermal growth factor receptor (EGFR) T790M mutations

Meeting Abstract

Riely, G. J.; Yu, H. A.; Arcila, M. E.; Hellmann, M. D.; Ladanyi, M.; Kris, M. G.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients

Meeting Abstract

Planchard, D.; Mazieres, J.; Riely, G. J.; Rudin, C. M.; Barlesi, F.; Quoix, E. A.; Souquet, P. J.; Socinski, M. A.; Switzky, J.; Ma, B.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC)

Meeting Abstract

Ou, S. H. I.; Bang, Y. J.; Camidge, D. R.; Riely, G. J.; Salgia, R.; Shapiro, G.; Solomon, B. J.; Engelman, J. A.; Kwak, E. L.; Clark, J. W.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs)

Meeting Abstract

Johnson, M. L.; Hart, E. M.; Rademaker, A.; Weitner, B. B.; Urman, A.; Simm, H. D.; Fountas, L. M.; Worden, R.; Patel, J. D.; Miller, V. A.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naive and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC)

Meeting Abstract

Gainor, J. F.; Varghese, A. M.; Ou, S. H. I.; Kabraji, S.; Awad, M. M.; Katayama, R.; Pawlak, A.; Mino-Kenudson, M.; Yeap, B. Y.; Riely, G. J.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials

Meeting Abstract

Drilon, A. E. D.; Wang, L.; Hasanovic, A.; Joubert, P.; Kris, M. G.; Riely, G. J.; Ladanyi, M.; Rizvi, N. A.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) in patients (PTS) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIS)

Meeting Abstract

Yu, H. A.; Johnson, M. L.; Urman, A.; Rademaker, A.; Hart, E.; Weitner, B. B.; Patel, J. D.; Kris, M.; Riely, G.
Journal of Thoracic Oncology (2013)

Fulltext@MSK | Save

Comparison of the characteristics and clinical course of patients with metastatic KRAS mutant lung cancers

Meeting Abstract

Riely, G.; Yu, H. A.; Sima, C. S.; Shen, R. L.; Kass, S. L.; Kris, M. G.; Ladanyi, M.
Journal of Thoracic Oncology (2013)

Fulltext@MSK | Save

Prospective molecular evaluation of small cell lung cancer (SCLC) utilizing the comprehensive mutation analysis Program at Memorial Sloan-Kettering Cancer Center (MSKCC)

Meeting Abstract

Pietanza, M. C.; Varghese, A.; Won, H.; Rekhtman, N.; Wang, L.; Travis, W. D.; Paik, P. K.; Riely, G. J.; Zakowski, M. F.; Ladanyi, M.; more...
Journal of Thoracic Oncology (2013)

Fulltext@MSK | Save